Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 ...
Tag: immunochemotherapy
